A financing contribution of EUR 2 million is shared by institutional investors “The BioScience Venture Group”, “V+ GmbH & Co Fonds 2 KG” and “V+ GmbH & Co Fonds 3 KG”, and by private investors from Germany, Switzerland and the USA. Based on a previous and substantial capital increase in the year 2011, APEPTICO had already secured a research grant of EUR 1.4 million from the Austrian Research Promotion Agency (FFG) by the end of 2011.
Dr. Bernhard Fischer, CEO of APEPTICO commented: “We are delighted to have secured our third equity financing with an international syndicate of venture capital, private investors and the FFG. This round C financing enables us to continue the clinical development of our lead peptide AP301. AP301 will be assessed in a “proof of concept” study in intensive care patients to investigate the clinical effect of repetitive orally inhaled doses of AP301 on alveolar liquid clearance in acute lung injury.
APEPTICO completes a EUR 3.4 million financing round
The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.
As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.